Impact of race on outcomes in intermediate-risk acute myeloid leukemia

[1]  J. Byrd,et al.  Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. , 2020, Cancer discovery.

[2]  B. Hobbs,et al.  The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. , 2019, Blood.

[3]  R. Foà,et al.  GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. , 2019, Blood.

[4]  Jong Y. Park,et al.  Racial/ethnic, age and sex disparities in leukemia survival among adults in the United States during 1973-2014 period , 2019, PloS one.

[5]  A. Seif,et al.  Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment , 2019, Leukemia & lymphoma.

[6]  J. Armitage,et al.  Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. , 2018, Blood advances.

[7]  N. Schneiderman,et al.  Association Between Sustained Poverty and Changes in Body Mass Index, 1990–2015: The Coronary Artery Risk Development in Young Adults Study , 2018, American journal of epidemiology.

[8]  Yan Li,et al.  Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population , 2018, Journal of Hematology & Oncology.

[9]  K. Pradhan,et al.  Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia. , 2017, Blood advances.

[10]  J. Griggs,et al.  Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Zheng,et al.  A marginal structural modeling strategy investigating short and long‐term exposure to neighborhood poverty on BMI among U.S. black and white adults , 2017, Health & place.

[12]  Shannon R. McCurdy,et al.  Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide , 2017, Haematologica.

[13]  R. Shi,et al.  Insurance Status and Other Non-biological Factors Predict Outcomes in Acute Myelogenous Leukemia: Analysis of Data from the National Cancer Database. , 2016, Anticancer research.

[14]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[15]  R. Shi,et al.  Predictors of Survival in Acute Myeloid Leukemia by Treatment Modality. , 2016, Anticancer research.

[16]  R. Vij,et al.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.

[17]  B. Mitchell,et al.  Understanding disparities in leukemia: a national study , 2012, Cancer Causes & Control.

[18]  H. Brenner,et al.  Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups , 2012, Haematologica.

[19]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[20]  L. Koniaris,et al.  Effects of Poverty and Race on Outcomes in Acute Myeloid Leukemia , 2011, American journal of clinical oncology.

[21]  S. Park,et al.  Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia , 2008, Journal of Korean medical science.

[22]  Shari Bolen,et al.  Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review , 2008, Cancer.

[23]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[24]  S. Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[25]  Edward J. Lee,et al.  Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. , 2004, Blood.

[26]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.